nach oben

Erschienen in:

07.12.2018 | Original Article

Receptor Tyrosine Kinase EphB3: a Prognostic Indicator in Colorectal Carcinoma

verfasst von: Zhuoqi Xuan, Jianming Huang, Lin Gao, Yong Wang, Jiandong Wang, Yueming Sun

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Although EphB3 expression is down-regulated in colorectal cancer (CRC) cells compared with normal intestinal epithelial cells, the relationship between EphB3 expression and clinicopathological parameters in CRC is unclear. We examined EphB3 expression in 128 CRC tissue specimens and in 19 adenoma specimens using immunohistochemistry. The relationships between EphB3 expression and clinicopathological parameters, KRAS mutations, BRAF V600E mutation, MSI and survival were evaluated using Spearman’s rank correlation and Kaplan–Meier survival analyses, respectively. CpG methylation in the EphB3 promoter was examined in four human CRC cell lines and tissues. EphB3 was strongly expressed in all normal intestinal epithelial cells (128/128) and adenoma cells (19/19). In CRC tumor cells, EphB3 expression was negative or weak in 41.4% (53/128), moderate in 26.6% (34/128), and strong in 32.0% (41/128) of samples. EphB3 expression was negatively associated with invasive depth (P = 0.016, r_s = −0.213), lymph node metastasis (P = 0.000, r_s = −0.490), and TNM stage (P = 0.000, r_s = −0.390), and was positively associated with poor differentiation (P = 0.001, r_s = 0.290), BRAF V600E mutation (P = 0.008, r_s = 0.235), and longer overall survival (P < 0.001). In multivariate analysis, EphB3 expression (P = 0.007) and lymph node metastasis (P < 0.001) were independent prognostic factors for poor survival. Hypermethylation of the EphB3 promoter was detected in cell lines and CRC tissues. EphB3 is down-regulated in CRC compared to normal mucosa. Hypermethylation of CpG island is contributed to downregulation of EphB3 in CRC. EphB3 expression in tumor cells may be a useful prognostic indicator for patients with CRC.

(1997) Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee. Cell 90(3):403–404

Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F (1987) A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238(4834):1717–1720CrossRef

Wilkinson DG (2001) Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2(3):155–164. https://doi.org/10.1038/35058515 CrossRefPubMed

Xu Q, Mellitzer G, Robinson V, Wilkinson DG (1999) In vivo cell sorting in complementary segmental domains mediated by Eph receptors and ephrins. Nature 399(6733):267–271. https://doi.org/10.1038/20452 CrossRefPubMed

Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133(1):38–52. https://doi.org/10.1016/j.cell.2008.03.011 CrossRefPubMed

Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L (2003) High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163(6):2271–2276. https://doi.org/10.1016/S0002-9440(10)63584-5 CrossRefPubMedPubMedCentral

Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10(15):5145–5150. https://doi.org/10.1158/1078-0432.CCR-03-0589

Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, Maruyama K, Isogaki J, Kanaoka S, Ihara M, Tanaka M, Kanamori M, Nakamura T, Shinmura K, Sugimura H (2005) Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24(36):5637–5647. https://doi.org/10.1038/sj.onc.1208720 CrossRefPubMed

Chiu ST, Chang KJ, Ting CH, Shen HC, Li H, Hsieh FJ (2009) Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. Carcinogenesis 30(9):1475–1486. https://doi.org/10.1093/carcin/bgp133 CrossRefPubMed

10.

Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick A, Himanen JP, Chaganti RS, Wendel HG (2011) The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147(3):554–564. https://doi.org/10.1016/j.cell.2011.09.035 CrossRefPubMedPubMedCentral

11.

Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, Asao T, Kuwano H (2004) Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 11(3):605–611PubMed

12.

Gao W, Zhang Q, Wang Y, Wang J, Zhang S (2017) EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas. APMIS 125(2):122–127. https://doi.org/10.1111/apm.12646 CrossRefPubMed

13.

Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS, Storkus WJ (2005) Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 11(1):226–231

14.

Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM (2009) Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15(13):4423–4430. https://doi.org/10.1158/1078-0432.CCR-09-0473

15.

Wang L, Hu H, Tian F, Zhou W, Zhou S, Wang J (2015) Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomas. Int J Clin Exp Pathol 8(10):13374–13380PubMedPubMedCentral

16.

Bai YQ, Zhang JY, Bai CY, Xu XE, Wu JY, Chen B, Wu ZY, Wang SH, Shen J, Shen JH, Yao XD, Gao LZ, Wu B, Gu HL, Liu XH, Li X, Li EM, Xu LY (2015) Low EphA7 expression correlated with lymph node metastasis and poor prognosis of patients with esophageal squamous cell carcinoma. Acta Histochem Cytochem 48(3):75–81. https://doi.org/10.1267/ahc.14054 CrossRefPubMedPubMedCentral

17.

Li S, Wu Z, Ma P, Xu Y, Chen Y, Wang H, He P, Kang Z, Yin L, Zhao Y, Zhang X, Xu X, Ma X, Guan M (2017) Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression. Cell Death Dis 8(10):e3122. https://doi.org/10.1038/cddis.2017.507 CrossRefPubMedPubMedCentral

18.

Dawson DW, Hong JS, Shen RR, French SW, Troke JJ, Wu YZ, Chen SS, Gui D, Regelson M, Marahrens Y, Morse HC 3rd, Said J, Plass C, Teitell MA (2007) Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 26(29):4243–4252. https://doi.org/10.1038/sj.onc.1210211 CrossRefPubMedPubMedCentral

19.

Bohme B, Holtrich U, Wolf G, Luzius H, Grzeschik KH, Strebhardt K, Rubsamen-Waigmann H (1993) PCR mediated detection of a new human receptor-tyrosine-kinase, HEK 2. Oncogene 8(10):2857–2862PubMed

20.

Baker RK, Vanderboom AK, Bell GW, Antin PB (2001) Expression of the receptor tyrosine kinase gene EphB3 during early stages of chick embryo development. Mech Dev 104(1–2):129–132CrossRef

21.

Kang JU, Koo SH, Kwon KC, Park JW, Kim JM (2009) Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 9:237. https://doi.org/10.1186/1471-2407-9-237 CrossRefPubMedPubMedCentral

22.

Ji XD, Li G, Feng YX, Zhao JS, Li JJ, Sun ZJ, Shi S, Deng YZ, Xu JF, Zhu YQ, Koeffler HP, Tong XJ, Xie D (2011) EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res 71(3):1156–1166. https://doi.org/10.1158/0008-5472.CAN-10-0717 CrossRefPubMed

23.

Li G, Ji XD, Gao H, Zhao JS, Xu JF, Sun ZJ, Deng YZ, Shi S, Feng YX, Zhu YQ, Wang T, Li JJ, Xie D (2012) EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. Nat Commun 3:667. https://doi.org/10.1038/ncomms1675 CrossRefPubMed

24.

Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T, Clevers H (2002) Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111(2):251–263CrossRef

25.

Jagle S, Ronsch K, Timme S, Andrlova H, Bertrand M, Jager M, Proske A, Schrempp M, Yousaf A, Michoel T, Zeiser R, Werner M, Lassmann S, Hecht A (2014) Silencing of the EPHB3 tumor-suppressor gene in human colorectal cancer through decommissioning of a transcriptional enhancer. Proc Natl Acad Sci U S A 111(13):4886–4891. https://doi.org/10.1073/pnas.1314523111 CrossRefPubMedPubMedCentral

26.

Ronsch K, Jager M, Schopflin A, Danciu M, Lassmann S, Hecht A (2011) Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer. Epigenetics 6(5):610–622CrossRef

27.

Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435(7045):1126–1130. https://doi.org/10.1038/nature03626 CrossRefPubMed

Titel: Receptor Tyrosine Kinase EphB3: a Prognostic Indicator in Colorectal Carcinoma
verfasst von: Zhuoqi Xuan
Jianming Huang
Lin Gao
Yong Wang
Jiandong Wang
Yueming Sun
Publikationsdatum: 07.12.2018
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 1/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-018-0562-x

Rab23 Promotes Hepatocellular Carcinoma Cell Migration Via Rac1/TGF-β Signaling

Original Article

Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome

Letter to the Editor

Hormone Replacement Therapy in Cancer Survivors – Review of the Literature

Open Access
Review

LncRNA CASC9 Suppressed the Apoptosis of Gastric Cancer Cells through Regulating BMI1

Original Article

Next-Generation Sequencing Identifies Novel RTK VUSs in Breast Cancer with an Emphasis on ROS1, ERBB4, ALK and NTRK3

Letter to the Editor

Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis

Review

Neu im Fachgebiet Onkologie

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

22.01.2025
Prostatakarzinom
Nachrichten

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Bei Achalasie auf Candidiasis der Speiseröhre achten!

21.01.2025
Achalasie
Nachrichten

Bei Achalasie-Betroffenen sollte man immer auch auf Candida-Infektionen achten, warnen Forschende aus Rotterdam. In ihrer Studie ließ die Pilzinfektion das Risiko für ein Ösophaguskarzinom massiv steigen.

Adipositas als negativer Prognosefaktor bei Kindern mit Krebs

Eine kanadische Studie weist darauf hin, dass Übergewicht zum Zeitpunkt der Krebsdiagnose ein unabhängiger Risikofaktor für schlechtere Überlebenschancen bei erkrankten Kindern und Jugendlichen sein könnte. Allerdings sind nicht alle Patientinnen und Patienten gleichermaßen betroffen.

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

20.01.2025
Risikofaktoren für Krebserkrankungen
Nachrichten

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Receptor Tyrosine Kinase EphB3: a Prognostic Indicator in Colorectal Carcinoma

Abstract

Weitere Artikel der Ausgabe 1/2020

Rab23 Promotes Hepatocellular Carcinoma Cell Migration Via Rac1/TGF-β Signaling

Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome

Hormone Replacement Therapy in Cancer Survivors – Review of the Literature

LncRNA CASC9 Suppressed the Apoptosis of Gastric Cancer Cells through Regulating BMI1

Next-Generation Sequencing Identifies Novel RTK VUSs in Breast Cancer with an Emphasis on ROS1, ERBB4, ALK and NTRK3

Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis

Neu im Fachgebiet Onkologie

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

Bei Achalasie auf Candidiasis der Speiseröhre achten!

Adipositas als negativer Prognosefaktor bei Kindern mit Krebs

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten